Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cobicistat + PLX8394 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cobicistat | Tybost | GS 9350|Evotaz|Genvoya|Prezcobix|Rezolsta|Stribild | Tybost (cobicistat) is an inhibitor of human cytochrome P450 3A (CYP3A), which potentially enhances exposure to other co-administered drugs (PMID: 24900196, PMID: 35933915). Tybost (cobicistat) is FDA approved to increase systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection (FDA.gov). | |
| PLX8394 | PLX 8394|PLX-8394|FORE8394|FORE-8394|FORE 8394|Plixorafenib | BRAF Inhibitor 26 CRAF Inhibitor 12 | PLX8394 is a RAF inhibitor that inhibits wild-type and mutant BRAF, as well as CRAF, and does not paradoxically activate MAPK signaling, potentially resulting in decreased proliferation of BRAF-mutant tumor cells (PMID: 26466569, PMID: 24283590, PMID: 28659148, PMID: 30559419). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|